Literature DB >> 15133868

Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection.

Jun Cui1, Bao-Wei Dong, Ping Liang, Xiao-Ling Yu, De-Jiang Yu.   

Abstract

AIM: To explore the effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma (HCC) patients undergoing tumor resection.
METHODS: Primary HCC patients underwent tumor resection were retrospectively analysed. The maximum size of the tumor was less than 5 cm, there was only one nodule in each patient. No chemoembolization was performed before resection. They were followed up after resection, and the time of recurrence was recorded. They were divided into 2 groups: group A (15 cases): tumor recurrence within 1 year after tumor resection, and group B (15 cases): with or without tumor recurrence 2 years after tumor resection. Pathological slices were made with tumor wax-sample. Immunohistochemistry staining was performed with c-myc, Ki-67, MMP-2 and VEGF monoclonal antibodies. Staining intensity was quantitatively analysed with a pathological diagram-writing analyzing system. The expressing intensity differences of stained molecules in cancer tissue and para-cancer were analysed.
RESULTS: c-myc, Ki-67, MMP-2 and VEGF expressing intensities in cancer tissue in group A were higher than those in group B (P values were 0.010, 0.030, 0.022 and 0.004, respectively), but they were not significantly different in para-cancer tissue in groups A and B (P values were 0.334, 0.343, 0.334 and 0.334, respectively).
CONCLUSION: The expression of c-myc, Ki-67, MMP-2 and VEGF in cancer tissue is related to the recurrence of HCC after tumor resection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133868      PMCID: PMC4656299          DOI: 10.3748/wjg.v10.i10.1533

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme.

Authors:  J Cheng; J Luo; X Zhang; J Hu; H Hui; C Wang; A Stern
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

2.  Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma.

Authors:  Hitoshi Shirahashi; Isao Sakaida; Shuji Terai; Koji Hironaka; Noriyoshi Kusano; Kiwamu Okita
Journal:  Liver       Date:  2002-10

3.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.

Authors:  M Määttä; Y Soini; A Liakka; H Autio-Harmainen
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

4.  [Correlation of c-myc gene amplification, MTS1/p16 gene alternation, and HBV infection in human hepatocellular carcinoma].

Authors:  J Zhang; K Wang; S Cong; F Qiu; X Wang; P Wang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2001-10

5.  Reduction of c-myc expression by an antisense approach under Cre/loxP switching induces apoptosis in human liver cancer cells.

Authors:  H Ebinuma; H Saito; M Kosuga; K Wakabayashi; Y Saito; T Takagi; N Nakamoto; T Okuyama; H Ishii
Journal:  J Cell Physiol       Date:  2001-07       Impact factor: 6.384

6.  EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation.

Authors:  T Aoki; S Inoue; H Imamura; J Fukushima; S Takahashi; T Urano; K Hasegawa; T Ogushi; Y Ouchi; M Makuuchi
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

7.  Expression of vascular endothelial growth factor and matrix metalloproteinase-2 correlates with the invasion and metastasis of hepatocellular carcinoma.

Authors:  Zhimin Liu; Lunan Yan; Tao Xiang; Lili Jiang; Bin Yang
Journal:  Sheng Wu Yi Xue Gong Cheng Xue Za Zhi       Date:  2003-06

8.  [Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma].

Authors:  Zheng-ping Xiong; Shu-ren Yang; En-hua Xiao; Shun-ke Zhou; Zi-shu Zhang; Zhao-yu Liang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2003-11

9.  A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma.

Authors:  Y Ishii; Y Nakasato; S Kobayashi; Y Yamazaki; T Aoki
Journal:  J Exp Clin Cancer Res       Date:  2003-09

10.  Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

Authors:  Woo Sung Moon; Ki Hoon Rhyu; Myoung Jae Kang; Dong Geun Lee; Hee Chul Yu; Jung Ho Yeum; Gou Young Koh; Andrzej S Tarnawski
Journal:  Mod Pathol       Date:  2003-06       Impact factor: 7.842

View more
  9 in total

Review 1.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

2.  The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus.

Authors:  Zhengbin Zhang; Dylan Harris; Virendra N Pandey
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

3.  Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Authors:  Matthias Pinter; Wolfgang Sieghart; Monika Schmid; Bernhard Dauser; Gerald Prager; Hans Peter Dienes; Michael Trauner; Markus Peck-Radosavljevic
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

4.  Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice.

Authors:  Liyuan Li; Maoxiang Qian; I-Hsuan Chen; David Finkelstein; Arzu Onar-Thomas; Melissa Johnson; Christopher Calabrese; Armita Bahrami; Dolores H López-Terrada; Jun J Yang; W Andy Tao; Liqin Zhu
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307

5.  Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.

Authors:  Jian Kong; Jinge Kong; Bing Pan; Shan Ke; Shuying Dong; Xiuli Li; Aimin Zhou; Lemin Zheng; Wen-bing Sun
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

6.  mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.

Authors:  T Scheller; C Hellerbrand; C Moser; K Schmidt; A Kroemer; S M Brunner; H J Schlitt; E K Geissler; S A Lang
Journal:  Br J Cancer       Date:  2015-02-17       Impact factor: 7.640

7.  Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma.

Authors:  Honglei Jiang; Dan Wu; Dong Xu; Hao Yu; Zheming Zhao; Dongyan Ma; Junzhe Jin
Journal:  Int J Biol Sci       Date:  2017-05-16       Impact factor: 6.580

Review 8.  Anti-angiogenic strategies in gastrointestinal malignancies.

Authors:  Jonathan Whisenant; Emily Bergsland
Journal:  Curr Treat Options Oncol       Date:  2005-09

9.  Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.

Authors:  Fei Ji; Zhi-Heng Zhang; Yi Zhang; Shun-Li Shen; Qing-Hua Cao; Long-Juan Zhang; Shao-Qiang Li; Bao-Gang Peng; Li-Jian Liang; Yun-Peng Hua
Journal:  BMC Cancer       Date:  2018-04-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.